AbbVie Lutikizumab Hits Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial

AbbVie announced primary results from the Phase 3 INTREPID trial: lutikizumab significantly increased the hidradenitis suppurativa clinical response 75 (HiSCR75) response rate at week 16 versus placebo, meeting the primary endpoint. The drug also met 8 ranked secondary endpoints, including significant improvement in HS-related skin pain at week 8 and a significant reduction in HS flare occurrence over the first 16 weeks, reflecting outcomes assessed by both patients and physicians.